ArticleClinical proteomics2025
In-depth analysis of data characteristics and comparative evaluation of dda and dia accuracy in label-free quantitative proteomics of biological samples.
Article in Clinical proteomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Identification of Gβ5 Interactome Associated with Neuronal Development in Neuro-2a Cells through miniTurbo Proximity Labeling.ACS omega · 2026Article
- Mechanisms ofJournal of fungi (Basel, Switzerland) · 2026Article
- Molecular Solution to the Paradox of Ancient Brain Preservation.Journal of proteome research · 2026Article
- Bypassing Androgens: Retina-Targeted 17β-Estradiol Delivery via DHED Eye Drops Ameliorates Orchiectomy-Induced Shifts in the Male Rat Visual Cortex Proteome.Antioxidants (Basel, Switzerland) · 2026Article
- Advances in proteomics research related to semaglutide: evidence from humans and animals.Journal of endocrinological investigation · 2026Review
- Quantitative Proteomic Profiling of Pinctada fucata Shell Nacre Defines a Solubility-Based Type Classification of Shell Matrix Proteins.Marine biotechnology (New York, N.Y.) · 2026Article
- Enhanced Proteomics Analysis with a Novel Recombinant Chymotrypsin Analogue Engineered for High Cleavage Specificity.Journal of proteome research · 2026Article
- BioProEV: A Bioinformatics Pipeline for Biologically-Relevant Handling of Missing Values in the Analysis of Extracellular Vesicles by Mass Spectrometry.Journal of extracellular biology · 2026Article
- Proteomics in Acute Myeloid Leukemia: Current Applications in Precision Medicine and Targeted Immunotherapy.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Data-Dependent Acquisition (DDA) and Data-Independent Acquisition (DIA) are widely used in MS-based proteomics. However, a comprehensive evaluation of their data characteristics-including protein and peptide identification, differential expression analysis, and the performance in revealing biological insights-remains lacking. In this study, we conducted a systematic comparison of DDA and DIA across three model sample types: one disease model, two drug-treated models, and their respective controls. Our analysis extended beyond conventional metrics such as total protein and peptide counts, precision, and accuracy, to include data completeness, detection of positive control markers, reproducibility, functional annotation reliability, and sources of methodological variation. The results demonstrated that DIA outperformed DDA in terms of protein identification (disease group: 7,735 vs. 5,067; drug-treated group 1: 7,987 vs. 4,605), quantitative coverage (average quantifiable protein ratio: DIA 98-99% vs. DDA 95-96%), and reproducibility (intragroup correlation coefficients: DIA > 0.98 vs. DDA 0.93-0.98). We also found DIA exhibited lower variability (intragroup CV < 10% vs. > 15% for DDA) and improved accuracy for low-abundance and housekeeping proteins. Additionally, the functional enrichment analyses further revealed DIA's superior capability in detecting pathway activation. Finally, discrepancies between DIA and DDA were primarily attributed to proteins identified with ≤ 5 peptides, the exclusion of single-peptide proteins enhanced overall data quality. Overall, this study systematically assess the overall capabilities of DDA and DIA approaches in uncovering biologically relevant findings and driving mechanistic insights within authentic pharmacological and disease models, thereby offering practical guidance for methodological choices in future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.